{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:36:30Z","timestamp":1793903790582,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T00:00:00Z","timestamp":1384300800000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Hellenic Society of Cardiology"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.jacc.2012.06.057","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T21:08:41Z","timestamp":1350508121000},"page":"2053-2060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Lipoprotein-Associated Phospholipase A2 Bound on High-Density Lipoprotein Is Associated With Lower Risk for Cardiac Death in Stable Coronary Artery Disease Patients"],"prefix":"10.1016","volume":"60","author":[{"given":"Loukianos S.","family":"Rallidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos C.","family":"Tellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Varounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Charalampopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zolindaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Dagres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Anastasiou-Nana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros D.","family":"Tselepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2012.06.057_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1567-5688(02)00045-4","article-title":"Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase","volume":"3","author":"Tselepis","year":"2002","journal-title":"Atheroscler Suppl"},{"issue":"suppl","key":"10.1016\/j.jacc.2012.06.057_bib2","doi-asserted-by":"crossref","first-page":"41F","DOI":"10.1016\/j.amjcard.2008.04.018","article-title":"Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker","volume":"101","author":"Corson","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2012.06.057_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1006\/bbrc.1999.1066","article-title":"Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma","volume":"261","author":"Asano","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacc.2012.06.057_bib4","first-page":"25","article-title":"Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature","volume":"37","author":"Madjid","year":"2010","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.jacc.2012.06.057_bib5","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1016\/S0021-9258(18)61335-3","article-title":"Human plasma platelet-activating factor acetylhydrolase","volume":"262","author":"Stafforini","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2012.06.057_bib6","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/01.ATV.0000244681.72738.bc","article-title":"Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis","volume":"26","author":"Kolodgie","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl","key":"10.1016\/j.jacc.2012.06.057_bib7","doi-asserted-by":"crossref","first-page":"23F","DOI":"10.1016\/j.amjcard.2008.04.015","article-title":"Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention","volume":"101","author":"Anderson","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2012.06.057_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/eurheartj\/ehn502","article-title":"Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study","volume":"30","author":"Tsimikas","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2012.06.057_bib9","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","article-title":"Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies","volume":"375","author":"Thompson","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.06.057_bib10","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1161\/ATVBAHA.107.151670","article-title":"Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease","volume":"27","author":"Sabatine","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2012.06.057_bib11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1373\/clinchem.2006.066845","article-title":"High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients","volume":"52","author":"Corsetti","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2012.06.057_bib12","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.ATV.0000222983.73369.c8","article-title":"Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress","volume":"26","author":"Koenig","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2012.06.057_bib13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1194\/jlr.M300086-JLR200","article-title":"Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis","volume":"44","author":"Blankenberg","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2012.06.057_bib14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/01.CIR.0000156457.35971.C8","article-title":"Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study","volume":"111","author":"Winkler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.06.057_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/eurheartj\/ehi010","article-title":"Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up","volume":"26","author":"Brilakis","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2012.06.057_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bbalip.2009.02.015","article-title":"The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma","volume":"1791","author":"Tellis","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacc.2012.06.057_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1476-511X-10-170","article-title":"Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): a review","volume":"10","author":"Silva","year":"2011","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacc.2012.06.057_bib18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.numecd.2005.08.006","article-title":"Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk","volume":"16","author":"Panagiotakos","year":"2006","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2012.06.057_bib19","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","article-title":"International physical activity questionnaire: 12-country reliability and validity","volume":"35","author":"Craig","year":"2003","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.jacc.2012.06.057_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","article-title":"Recommendations for chamber quantification","volume":"7","author":"Lang","year":"2006","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2012.06.057_bib21","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1161\/01.ATV.15.10.1764","article-title":"PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma","volume":"15","author":"Tselepis","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2012.06.057_bib22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0022-2275(20)30167-X","article-title":"Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia","volume":"43","author":"Tsimihodimos","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2012.06.057_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737159.5.1.9","article-title":"PLAC test for identification of individuals at increased risk for coronary heart disease","volume":"5","author":"Hoogeveen","year":"2005","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jacc.2012.06.057_bib24","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1373\/clinchem.2005.058404","article-title":"Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma","volume":"51","author":"Gazi","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2012.06.057_bib25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1194\/jlr.M200452-JLR200","article-title":"Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins","volume":"44","author":"Tsimihodimos","year":"2003","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.jacc.2012.06.057_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.ATV.21.4.481","article-title":"HDL and the inflammatory response induced by LDL-derived oxidized phospholipids","volume":"21","author":"Navab","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2012.06.057_bib27","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1096\/fj.99-1029com","article-title":"HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-\/- mice","volume":"14","author":"Theilmeier","year":"2000","journal-title":"FASEB J"},{"key":"10.1016\/j.jacc.2012.06.057_bib28","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1161\/01.CIR.103.20.2495","article-title":"Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice","volume":"103","author":"Quarck","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.06.057_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2004.10.025","article-title":"Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta","volume":"179","author":"Turunen","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2012.06.057_bib30","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1161\/CIRCULATIONAHA.104.476242","volume":"111","author":"Arakawa","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.06.057_bib31","doi-asserted-by":"crossref","first-page":"17099","DOI":"10.1074\/jbc.M802394200","article-title":"Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein","volume":"283","author":"Gardner","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2012.06.057_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.plefa.2004.10.021","article-title":"Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome","volume":"72","author":"Rizos","year":"2005","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.jacc.2012.06.057_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11745-008-3251-9","article-title":"Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome","volume":"44","author":"Lagos","year":"2009","journal-title":"Lipids"},{"key":"10.1016\/j.jacc.2012.06.057_bib34","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1161\/ATVBAHA.107.147280","article-title":"Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2","volume":"27","author":"Saougos","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2012.06.057_bib35","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/hq0202.102918","article-title":"Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB","volume":"22","author":"Tsimihodimos","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2012.06.057_bib36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1253\/circj.71.214","article-title":"Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation","volume":"71","author":"Okamura","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2012.06.057_bib37","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","volume":"51","author":"Mohler","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.06.057_bib38","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","article-title":"Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque","volume":"118","author":"Serruys","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.06.057_bib39","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.2174\/138161211798220936","article-title":"Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2)","volume":"17","author":"Tselepis","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacc.2012.06.057_bib40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1042\/bj3380479","article-title":"Lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor","volume":"338","author":"MacPhee","year":"1999","journal-title":"Biochem J"},{"key":"10.1016\/j.jacc.2012.06.057_bib41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2010.07.006","article-title":"Study design and rationale for the clinical outcomes of the STABILITY trial (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) comparing darapladib versus placebo in patients with coronary heart disease","volume":"160","author":"White","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2012.06.057_bib42","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ahj.2011.07.018","article-title":"Study design and rationale for the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome","volume":"162","author":"O'Donoghue","year":"2011","journal-title":"Am Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109712043112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109712043112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:54:39Z","timestamp":1760014479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109712043112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":42,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0735109712043112"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2012.06.057","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein-Associated Phospholipase A2 Bound on High-Density Lipoprotein Is Associated With Lower Risk for Cardiac Death in Stable Coronary Artery Disease Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2012.06.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}